PDS Biotechnology Shares Outstanding vs. Book Value Per Share

PDSB Stock  USD 1.71  0.06  3.39%   
Based on the key profitability measurements obtained from PDS Biotechnology's financial statements, PDS Biotechnology Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess PDS Biotechnology's ability to earn profits and add value for shareholders. At present, PDS Biotechnology's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 6.18, whereas Book Value Per Share is forecasted to decline to 0.80.
For PDS Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PDS Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PDS Biotechnology Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PDS Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PDS Biotechnology Corp over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Return On Assets
(0.40)
Return On Equity
(1.28)
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

PDS Biotechnology Corp Book Value Per Share vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining PDS Biotechnology's current stock value. Our valuation model uses many indicators to compare PDS Biotechnology value to that of its competitors to determine the firm's financial worth.
PDS Biotechnology Corp is rated below average in shares outstanding category among its peers. It also is rated below average in book value per share category among its peers . The ratio of Shares Outstanding to Book Value Per Share for PDS Biotechnology Corp is about  47,353,291 . At present, PDS Biotechnology's Book Value Per Share is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PDS Biotechnology's earnings, one of the primary drivers of an investment's value.

PDS Book Value Per Share vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

PDS Biotechnology

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
37.41 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

PDS Biotechnology

Book Value per Share

 = 

Common Equity

Average Shares

 = 
0.79 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

PDS Book Value Per Share Comparison

PDS Biotechnology is currently under evaluation in book value per share category among its peers.

PDS Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in PDS Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PDS Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of PDS Biotechnology's change in net profit over the period of time. It can combine multiple indicators of PDS Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-43 M-45.2 M
Income Before Tax-44.3 M-46.6 M
Total Other Income Expense Net-1.3 M-1.2 M
Net Loss-42.9 M-45.1 M
Income Tax Expense-1.4 M-1.5 M
Interest Income2.8 MM
Net Loss-36.8 M-34.9 M
Net Interest Income-1.1 M-1.2 M
Net Loss-51.2 M-53.7 M
Non Operating Income Net Other49.5 K44 K
Change To NetincomeM6.3 M
Net Loss(1.39)(1.46)
Income Quality 0.78  0.75 
Net Income Per E B T 0.97  1.03 

PDS Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on PDS Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PDS Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PDS Biotechnology's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in PDS Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Use Investing Themes to Complement your PDS Biotechnology position

In addition to having PDS Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Restaraunts Hotels Motels Thematic Idea Now

Restaraunts Hotels Motels
Restaraunts Hotels Motels Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Restaraunts Hotels Motels theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaraunts Hotels Motels Theme or any other thematic opportunities.
View All  Next Launch
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
Check out Your Equity Center.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
To fully project PDS Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of PDS Biotechnology Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include PDS Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential PDS Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although PDS Biotechnology investors may work on each financial statement separately, they are all related. The changes in PDS Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on PDS Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.